In Reply We thank Woodcock et al for their response to our Viewpoint.1 We recognize the challenges of conveying the right level of information to multiple audiences, including clinicians, patients, and researchers. Nevertheless, the Letter does not resolve the “misconceptions” it claims underlie our Viewpoint, and we still have concerns about integrated drug reviews at the US Food and Drug Administration (FDA).
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Doshi P, Morten CJ, Herder M. Integrated Drug Reviews at the US Food and Drug Administration—Reply. JAMA Intern Med. Published online July 27, 2020. doi:10.1001/jamainternmed.2020.1978
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: